A randomized, double-blind, placebo-controlled, phase IIa trial of Ubiquinone, Ezetimibe/Simvastatin and Rosuvastatin assessing DNA damage and endogenous antioxidants in patients with Diabetic polyneuropathy

Trial Profile

A randomized, double-blind, placebo-controlled, phase IIa trial of Ubiquinone, Ezetimibe/Simvastatin and Rosuvastatin assessing DNA damage and endogenous antioxidants in patients with Diabetic polyneuropathy

Completed
Phase of Trial: Phase II

Latest Information Update: 15 Mar 2016

At a glance

  • Drugs Ezetimibe/simvastatin (Primary) ; Rosuvastatin (Primary) ; Ubidecarenone (Primary)
  • Indications Diabetic neuropathies
  • Focus Pharmacodynamics
  • Most Recent Events

    • 15 Mar 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top